How would you treat a young man with refractory AML after HIDAC induction who developed cerebellar toxicity to HIDAC and previously received doxorubicin (300 mg/m2) for lymphoma?
1 Answers
Mednet Member
Medical Oncology · Johns Hopkins University/Sidney Kimmel Cancer Center
CLAG-M (cladribine, Ara-C, mitoxantrone, with G-CSF priming)
